Intended for healthcare professionals

Papers And Originals

Clinical Trial of 6% Hydroxyethyl Starch (a New Plasma Expander)

Br Med J 1968; 3 doi: https://doi.org/10.1136/bmj.3.5621.783 (Published 28 September 1968) Cite this as: Br Med J 1968;3:783
  1. Toriola F. Solanke

    Abstract

    No adverse effects were seen in 29 patients given an intravenous infusion of 6% hydroxyethyl starch solution. Platelet counts had fallen by eight hours after infusion, but had reached pretransfusion levels by 24 hours. Two patients developed unusual bleeding post-operatively, which was possibly due to the infusion. Further investigations on the first stage of coagulation and prothrombin generation in patients receiving hydroxyethyl starch are required.

    Footnotes

    • * 6% Hydroxyethyl starch in 0.9% sodium chloride was supplied by Don Baxter Co., Glendale, California, U.S.A.